In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity
Authors: De Clerck Fred , Van de Water André , D'Aubioul Jan , Lu Hua Rong , Van Rossem Koen , Hermans An , Van Ammel Karel 
Published: March 2003

In addition to in silico and in vitro measurements, cardiac electrophysiology in experimental animals plays a decisive role in the selection of a potential `cardio‐safe' new chemical entity (NCE). The present synopsis critically reviews such in vivo techniques in experimental animals.In anaesthetized guinea‐pigs, surface ECG recordings readily identify the typical effects of Class I to IV anti‐arrhythmic compounds and of If blockers such as zatebradine on ECG intervals and morphology, but also of non‐cardiovascular NCEs affecting cardiac electrical activity via ion channels or neurogenic mechanisms. QT/RR plots indicate that bradycardia is a dominant effect of IKr blockers (dual modulation by IKr of sinus node activity and ventricular repolarization). Nevertheless, correction of QT with Bazett's formula usually distinguishes between drug‐induced heart rate reduction and real prolongation of ventricular repolarization (QTc).The anaesthetized guinea‐pig model thus is a useful tool for first line in vivo testing of an NCE for effects on cardiac electrophysiology, in particular when combined with measurements of drug levels in plasma and heart tissues.In anaesthetized dogs, advanced ECG analyses identify drug‐induced effects on atrial and ventricular intervals, on temporal and transmural dispersion of ventricular repolarization and on incidences of early after‐depolarizations. This can be combined with complete haemodynamic, pulmonary and pharmacokinetic analyses in one preparation.However, compound doses/plasma levels needed for effects on ventricular repolarization in this model are substantially higher than those identified in guinea‐pigs, at least for IKr blocking compounds. Therefore, we use this `information‐rich' canine model as a second line approach.In awake, trained and appropriately instrumented dogs, readings of surface ECG in combination with cardio‐haemodynamic and behavioural assessments can be performed after the administration of an NCE via the expected therapeutic route, including oral medication. However, at higher doses the compound under scrutiny may induce overall behavioural side‐effects, related to its primary pharmacological action, such as gastrokinetic repercussions or CNS‐mediated sedation or excitation. Such primary pharmacological effects are bound to compromise the evaluation of real drug‐induced changes on cardiac electrophysiology, readily identified by resource‐friendly setups in smaller animals. Therefore, we use such paradigms as an imperative, final cardiovascular check‐up, before a `First in Man' administration of the NCE.In anaesthetized, methoxamine‐challenged rabbits, arrhythmogenic effects of IKr blockers (torsades de pointes) and of dual channel INa/IKr blockers (conduction disturbances) are readily identified. Drug‐induced QT dispersion rather than a `simple' QTc prolongation determines the ventricular arrhythmogenic effect of IKr blockers. The latter effect also depends on the rate of drug delivery (plasma levels vs. heart level, equilibrium throughout the myocardium). Therefore, we use models sensitized for arrhythmogenesis to document further the profile of a comparatively `cardio‐safe' NCE.We conclude that the interpretation of an integrated profile of activity of an NCE on in vitro and in vivo cardiovascular parameters, in comparison with the characteristics of its primary pharmacology and target disease, determines its eventual selection via a scientific, rather than a `checklist' or `menu' approach to cardiovascular safety pharmacology. Appropriate tests in experimental animals play a key role in this process.